1.The Effects of Qing-nao-ding-tong Decoction on The Levels of IL-6 and TNF-? in Subarachnoid Hemorrhage
Yuzhou HE ; Chenyu JIN ; Wenlei HU
Journal of Zhejiang Chinese Medical University 2006;0(03):-
[Objective]To observe the effects of qing-nao-ding-tong decoction on the levels of IL-6 and TNF-? in subarachnoid hemorrhage.[Methods]Cases were randomly divided into integrated traditional Chinese and western medicine (TCW) groups,western medicine group and control group.After 2w treatment,the levels of IL-6 and TNF-? were contrasted.[Results]The levels of IL-6 and TNF-? were both raised.Combined with western medicine,qing-nao-ding-tong decoction could effectively reduce the levels of IL-6 and TNF-?.[Conclusion]Combined with western medicine,qing-nao-ding-tong decoction can effectively reduce the levels of IL-6 and TNF-? in patients with subarachnoid hemorrhage,and there is synergistic reaction between TCM and WM.
2.Hybrid procedure for pulmonary atresia with intact ventricular septum
Shoujun LI ; Weidan CHEN ; Ying ZHANG ; Hao ZHANG ; De WANG ; Zhongdong HUA ; Wenlei LI ; Shengshou HU
Chinese Journal of Thoracic and Cardiovascular Surgery 2011;27(5):273-276
Objective In patients with pulmonary atresia and intact ventricular septum ( PAIVS) without right ventricular-dependent coronaries, catheter techniques including the use of a sniff wire, lasers, and radiofrequency have been the most widely used initial therapy. However, percutaneous perforation and balloon valvuloplasty were associated with higher rate of procedural failure and serious complications. Methods We report our experience with a hybrid approach for pulmonary atresia with intact ventricular septum, combining surgery and interventional catheterization techniques. Between March 2005 and March 2010, hybrid procedure was carried out successfully in 30 newboms and infants with favorable anatomy. The age ranged from 1 day to 48 months with a mean of (4.59 ±3.21) months. The heart was exposed through median sternotomy. A pursestring suture was placed in the right ventricular outflow tract 2 cm away from the pulmonary trunk. Then a 16-gauge intravenous catheter was punctured through the right ventrical and perforated the atretic PV with the guidance of echocardiography. A guide wire was then inserted into the sheath and used to guide the balloon across the PV. Sequential dilations were performed until a full opening of the PV with the guidance of epicardial echocardiography. In patients < 3 months PDA ligation was performed followed by modified Blalock-Taussig (B-T) shunt. In patients > 3 months PDA ligation was not performed. A modified B-T shunt was inserted if severe systemic oxygen desaturation occurred after PDA ligation. Bidirectional Glenn shunt was performed for severe hypoplasia. Hybrid procedure was achieved in all patients. The simultaneous procedures included 25 cases of PDA ligation. 6 newborns underwent modified B-T shunt placement (3.5 to 5 mm) after pulmonary valvuloplasty and PDA ligation, and 2 patients > 1 month underwent modified B-T shunt. Another 2 patients were selected for univentricular palliative surgery because of a diminutive monopartite right ventricle and bidirectional Glenn procedure was performed. No pericardial effusion or cardiac tamponade was observed in all patients. Another case without PDA ligation underwent a modified B-T shunt because of hypoxemia three days after hybrid procedure, and the rest patients were discharged without any further surgical intervention.During the follow-up period of 1.5 to 62.0 months, 5 patients died. 25 (83.3%) survived and were all in New York Heart Association functional class 1. Peripheral oxygen saturation increased from 0.73 ± 0.08 to 0.94 ± 0.04 (P < 0.05). One patient remains in a single-ventricle pathway, whereas 24 patients achieved a two-ventricle circulation. Results Conclusion Perventricular balloon pulmonary valvuloplasty using a hybrid approach is a safe and feasible procedure for patients with PAIVS.
3.Comparision on Work Fatigue between the Disabled and the Healthy
Guoxing XIONG ; Wenlei XU ; Yue MENG ; Shanshan HU ; Zhihan SUN ; Dizun ZHAO
Chinese Journal of Rehabilitation Theory and Practice 2011;17(12):1193-1195
Objective To investigate the status of work fatigue of the disabled and the healthy so that we get to know their employment quality and compressive strength, and then provide the theory basis for the national policy formulation and vocational rehabilitation. Methods We randomly investigated 280 employees (220 disabled, 60 healthy people) in 3 companies from 3 provinces with Fatigue Impact Scale (FIS). Results There was no statistically significant difference between disabled and healthy people about work fatigue, and also that of 3 domains including psycho-social, cognitive and physical activity. After comparison of 40 items on FIS,the disabled had higher fatigue than that of the healthy in 4 items which belonged to psycho-social domain (P<0.05). Conclusion Disabled people are no less than healthy people in compression capability and working capability. They should believe in themselves, and their family and the employees should have more confidence about their work capability than before. Government should provide some support with them on job retention.
4.Clinical efficacy of Fufang Yangxue Tang for cancer-related anemia
China Modern Doctor 2015;(11):128-131
Objective To discuss clinical efficacy of Fufang Yangxue Tang for cancer-related anemia. Methods Clini-cal data of 120 cases with cancer-related anemia were respectively analyzed. 64 cases of control group were treated by EPO, and 56 cases of study group were treated by Fufang Yangxue Tang based on treatment of EPO. Clinical efficacy of two groups was compared. Results After treatment of 8 weeks, efficiency of study group was 67.9%, and performance status improvement rate was 82.1%, which were higher than control group (P<0.05);Hb and Hct levels after treatment of 4 weeks and 8 weeks increased compared with before treatment(P<0.01), and study group improved more(P<0.01). Conclusion Fufang Yangxue Tang combined with EPO in treatment of cancer-related anemia can improve clinical effi-cacy, improve performance status and Hb and Hct, worthy of clinical promotion.
5.Immune checkpoint inhibitors combined with TKIs as a bridge therapy for advanced HCC before liver transplantation
Binwei DUAN ; Wenlei LI ; Junning CAO ; Wenwen ZHANG ; Bingyang HU ; Jushan WU ; Gongming ZHANG ; Yabo OUYANG ; Shichun LU ; Guangming LI
Chinese Journal of Hepatobiliary Surgery 2022;28(1):28-32
Objective:To investigate the safety and efficacy of combining programmed death-1 (PD-1) with tyrosine kinase inhibitors (TKIs) in patients with advanced hepatocellular carcinoma (HCC) before liver transplantation(LT).Methods:The data of six males with a mean ± s. d. age of (57.5±4.3) years who were treated with PD-1 inhibitors combined with TKIs for advanced HCC before LT at Beijing You'an Hospital, Capital Medical University and the First Medical Center of Chinese PLA General Hospital were retrospectively analysed. The tumor stagings, the use of PD-1 inhibitors and TKIs with their discontinuation in pre-LT/post-LT liver function recovery durations, incidences of complication. The tumor recurrence and disease-free survival rates were determined on follow-up of these patients at outpatients clinics.Results:For the 6 patients included in this study, four patients were classified by the Barcelona Clinic Liver Cancer Staging (BCLC) as C and the China Liver Cancer Staging (CNLC) as Ⅲa, and two patients were classified by the BCLC staging as B and the CNLC asⅡb. The mean cycle of PD-1 inhibitor used was 5.5 (1-20), and the mean duration of PD-1 inhibitor discontinuation was 19.5 (12-45) days pre-LT. All patients who were treated with PD-1 inhibitors combined with TKIs reached the liver transplantation standard, and all successfully underwent orthotopic liver transplantation. The liver function recovered well without any serious complications post-LT. All the patients survived without developing any acute rejection or other complications. The follow-up time ranged from 8.2 to 27.3 months, with a median of 11.9 months. No patients had died, and 2 patients developed tumor recurrence. The median (range) tumor-free survival time was 10.9 (2.9-27.3) months.Conclusion:Patients with advanced HCC could benefit from combined PD-1 inhibitors with TKIs therapy pre-LT. There were no increased incidences of acute rejection and other complications post-LT.